Shares of Mainz Biomed (NASDAQ:MYNZ – Free Report) are set to reverse split before the market opens on Tuesday, December 3rd. The 1-40 reverse split was announced on Friday, November 29th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, December 2nd.
Mainz Biomed Stock Down 14.1 %
NASDAQ MYNZ traded down $0.04 during mid-day trading on Friday, reaching $0.22. 7,094,717 shares of the stock were exchanged, compared to its average volume of 1,350,238. The business’s fifty day simple moving average is $0.26 and its 200 day simple moving average is $0.39. Mainz Biomed has a 1-year low of $0.19 and a 1-year high of $1.79.
Wall Street Analyst Weigh In
Separately, HC Wainwright downgraded Mainz Biomed from a “buy” rating to a “neutral” rating in a research report on Monday.
Mainz Biomed Company Profile
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
Read More
- Five stocks we like better than Mainz Biomed
- Breakout Stocks: What They Are and How to Identify Them
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- Golden Cross Stocks: Pattern, Examples and Charts
- 3 Penny Stocks Ready to Break Out in 2025
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
